Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 11, 1998

View Archived Issues

Kotobuki selects development candidate from novel series with selectivity for COX-2

Novartis dives into renin inhibitor research; one compound selected for clinical testing

Biaryl uricosuric agents developed at Kotobuki

Merck Frosst reveals discoveries in the field of COX-2 inhibitors at ACS meeting

DDE-131: new apoptosis-inducing antitumor agent from WHI

Immune Response presents phase II data on psoriasis treatment

DuPont identifies SP-904 as potent and selective CRF1 receptor antagonist

Dimethoxy quinazoline derivative WHI-P180 inhibits mast cell mediator release

Texas Biotechnology announces positive data from phase IIa asthma study

Amgen initiates clinical trials of novel bone protective agent

Clinical studies on Hoe-901 reported at European diabetes meeting

Nicotine Inhaler launched nationwide in the U.S.

Troponin I blocks retinal angiogenesis in another animal model

Preclinical and clinical data support potential of MKC-733 in GI motor disorders

SB reports on potent analgesics with fewer side effects

Novel binary compounds with agonist-antagonist effects in vivo

Merck & Co. discovers another potent and selective COX-2 inhibitor

New anxiolytic PBI derivative discovered at R.W. Johnson

Selective PDE4 inhibitors discovered at Jouveinal presented at ACS meeting

U.K. filing announced for MED treatment option

Genzyme General to commercialize and distribute Biogen's Avonex in Japan

FDA recommends full approval of first new treatment for metastatic colorectal cancer in 40 years

Siga identifies lead antibiotic compound

Two new LTD4 antagonists from Pfizer with promising profiles

New agent for unstable bladder introduced in U.K.

CHF treatment now available in the U.K.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...